Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Curry

Vascular Surgery Olympia, WA Medical Doctor

NPI 1811974652 CMS profile 127983

128 Lilly Rd Ne Ste 205, Olympia, WA 98506

Open in the dashboard

General payments

$8,856

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Curry of Olympia, WA is reported in the CMS Open Payments database as having received $8,856 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,244 34
2024 General $1,388 41
2023 General $2,213 67
2022 General $834 28
2021 General $1,081 28
2020 General $572 19
2019 General $524 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Curry
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thomas Curry were reported at $2,244. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thomas Curry Vascular Surgery median Middle half National median
2019 $524 $796 $226–$2,363 $163
2020 $572 $348 $118–$1,110 $114
2021 $1,081 $471 $158–$1,421 $132
2022 $834 $725 $222–$2,183 $149
2023 $2,213 $836 $257–$2,440 $160
2024 $1,388 $909 $252–$2,619 $164
2025 $2,244 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,733 89 payments
  2. Penumbra, Inc. $1,255 9 payments
  3. W. L. Gore & Associates, Inc. $1,215 12 payments
  4. Boston Scientific Corporation $737 33 payments
  5. Abiomed $731 8 payments
  6. Silk Road Medical, Inc. $544 13 payments
  7. Cook Medical LLC $457 9 payments
  8. Medtronic Vascular, Inc. $431 17 payments
  9. Stryker Corporation $407 7 payments
  10. Inari Medical, Inc. $376 10 payments
  11. Other $970 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,250 225 payments
  2. Travel and Lodging $1,606 6 payments
Products named General payments · program years 2019–2025
  1. Indigo System $969 6 payments
  2. COREVALVE EVOLUT R $863 60 payments
  3. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $856 9 payments
  4. FLOWTRIEVER CATHETER, S $405 9 payments
  5. ARTIX MT $401 6 payments
  6. ENROUTE Transcarotid Stent $385 12 payments
  7. ENROUTE Transcarotid Neuroprotection System $385 12 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $343 2 payments
  9. Impella $333 6 payments
  10. ENDURANT IIS $261 12 payments
  11. Other $4,706 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

75

Median for Vascular Surgery: 122

Drug cost

$905

Median for Vascular Surgery: $14,135

Branded share of claims

54.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 23 $564
Clopidogrel Clopidogrel Bisulfate Brand 41 $229
Tamsulosin Hcl Generic 11 $112

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$116,297

Medicare's payments for the services billed

Medicare patients

268

Average age 75

Services billed

743

105 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 45%
Diabetes 43%
Arthritis 42%
Heart failure 37%
COPD 35%
Chronic kidney disease 34%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record